CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signaling pathway

Area of Science:

• Cardiology
• Molecular Biology
• Biochemistry

Background:

• CD9, a tetraspanin protein, is implicated in inflammation and cancer.
• Its role in pathological cardiac hypertrophy remains largely unexplored.

Purpose of the Study:

• To investigate the role of CD9 in pathological cardiac hypertrophy.
• To elucidate the underlying molecular mechanisms involving CD9 in cardiac hypertrophy.

Main Methods:

• Utilized a transaortic constriction (TAC) mouse model to induce cardiac hypertrophy.
• Employed CD9 knockdown and co-immunoprecipitation assays.
• Assessed cardiac function, heart weight, cardiomyocyte size, fibrosis, GP130 levels, and STAT3 phosphorylation.

Main Results:

• CD9 expression was upregulated in TAC-induced myocardial tissue.
• CD9 knockdown ameliorated cardiac dysfunction, reduced heart weight, cardiomyocyte size, and fibrosis.
• CD9 directly binds to GP130, reducing GP130 protein levels and STAT3 phosphorylation.
• GP130 knockdown counteracted the detrimental effects of CD9 on cardiac hypertrophy.

Conclusions:

• CD9 exacerbates pathological cardiac hypertrophy by modulating the GP130/STAT3 signaling pathway.
• CD9 represents a potential therapeutic target for treating pathological cardiac hypertrophy.